Fas apoptotic pathway (Fas pathway)

The Fas apoptotic pathway is a crucial extrinsic signaling cascade that regulates programmed cell death, or apoptosis, in various cell types. It is initiated when the Fas receptor (CD95/APO-1), a death receptor on the cell surface, binds to its ligand, FasL. This binding leads to the formation of a death-inducing signaling complex (DISC) and the activation of caspases, ultimately dismantling the cell. Beyond its primary role in apoptosis, the Fas pathway also participates in immune regulation, maintaining cellular homeostasis, and can activate non-apoptotic signaling pathways involved in cell migration, invasion, and proliferation. Dysregulation of this pathway is implicated in numerous diseases, including various cancers where resistance to Fas-mediated apoptosis contributes to tumor progression, and autoimmune diseases like Systemic Lupus Erythematosus and Type 1 Diabetes, where aberrant Fas signaling can lead to immune system dysfunction. Therapeutic strategies often involve modulating the Fas/FasL interaction, such as using FasL inhibitors to prevent excessive cell death in autoimmune or neurodegenerative conditions, or employing agonistic anti-Fas antibodies and certain chemotherapeutic drugs to induce apoptosis in cancer cells. However, challenges include overcoming cellular resistance mechanisms and ensuring targeted modulation to avoid broad impacts on immune function and cell viability.

Other names

Fas/FasL systemFas cell signaling pathwayextrinsic death pathwayCD95 pathwayAPO-1 pathway

Drugs targeting the Fas apoptotic pathway primarily modulate the interaction between the Fas receptor and its ligand, FasL, or interfere with downstream signaling components. FasL inhibitors block the binding of FasL to Fas, thereby preventing the initiation of apoptosis. Agonistic anti-Fas antibodies can directly bind to and activate the Fas receptor, mimicking FasL and triggering the apoptotic cascade. Some chemotherapeutic agents induce FasL expression or upregulate Fas, sensitizing cells to apoptosis, although some may act through Fas/FasL-independent mechanisms. Caspase inhibitors directly block the activity of key executioner enzymes in the pathway, preventing cell death. Certain agents aim to restore Fas-sensitivity in resistant cancer cells, while toxins like Acutolysin A can activate the pathway to induce apoptosis.